PFE - Pfizer Inc.
| Previous Close | 36.51 |
| Open | 36.89 |
| Bid | 36.60 x 3200 |
| Ask | 36.69 x 900 |
| Day's Range | 36.48 - 37.25 |
| 52 Week Range | 33.97 - 46.47 |
| Volume | 30,409,704 |
| Avg. Volume | 25,863,204 |
| Market Cap | 202.934B |
| Beta (3Y Monthly) | 0.43 |
| PE Ratio (TTM) | 16.95 |
| EPS (TTM) | 2.16 |
| Earnings Date | Oct 29, 2019 |
| Forward Dividend & Yield | 1.44 (3.94%) |
| Ex-Dividend Date | 2019-08-01 |
| 1y Target Est | 41.82 |
- MarketWatch
NFL legend Terry Bradshaw buys and sells $5 million planes the way some people flip houses
The NFL Hall of Famer spoke with MarketWatch about why losing $900,000 ended up being the best financial move he ever made, and why he spends so much time trying to help educate his fellow baby boomers.
- MarketWatch
Walgreens Boots, Pfizer share gains contribute to Dow's nearly 75-point jump
DOW UPDATE Shares of Walgreens Boots and Pfizer are seeing strong returns Friday morning, propelling the Dow Jones Industrial Average into positive territory. Shares of Walgreens Boots (WBA) and Pfizer (PFE) are contributing to the blue-chip gauge's intraday rally, as the Dow (DJIA) was most recently trading 72 points, or 0.
- Zacks
Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updates
FDA approves label expansion of Merck's (MRK) Keytruda and J&J's (JNJ) Erleada.
- GuruFocus.com
5 Companies Growing Earnings
Chipmakers Taiwan Semiconductor, Intel top the list Continue reading...
- Barrons.com
Pfizer Is Spinning Off Upjohn. What’s Left Will Be No Bargain, Analyst Says
J.P. Morgan’s Chris Schott told a look at what he calls New Pfizer, the biopharma business that will be left after the spinoff of the unit that makes drugs such as Viagra and Lipitor.
- Business Wire
Pfizer Presents Scientific Advancements in Cancer Care at the ESMO Congress 2019 Highlighting Expanded Portfolio
Presentations of interest include a late-breaking abstract on expanded Phase 3 data in BRAF-mutant metastatic colorectal cancer
- Zacks
Merck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma
Merck (MRK) receives accelerated approval for label expansion of Keytruda in combination with Lenvima for treating certain types of endometrial carcinoma. Its Ebola vaccine BLA gets priority review.
- Business Wire
Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call With Analysts
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 29, 2019. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2019 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors.
- Morningstar
Our Ultimate Stock-Pickers' Top 10 Dividend-Yielding Stocks
While the vast majority of our Ultimate Stock-Pickers are not dividend investors, a handful of them--Amana Trust Income AMANX , Columbia Dividend Income LBSAX , Oakmark Equity & Income OAKBX , and Parnassus Equity Income PRBLX --focus more heavily on income-producing stocks in their pursuit of investment return. Warren Buffett at Berkshire Hathaway BRK.B has spoken highly of companies that return capital to shareholders and is not against investing in and holding higher-yielding names, with three of Berkshire's top five holdings--wide-moat rated Wells Fargo WFC , Bank of America BAC , and Coca-Cola KO --accounting for about one third of the insurer's equity portfolio and yielding more than the S&P 500. As you may recall from previous articles, when we screen for top dividend-paying stocks among the holdings of our Ultimate Stock-Pickers, we try to find the highest-quality names that are currently held with conviction by our top managers.
- Zacks
Pfizer (PFE) Stock Moves -0.24%: What You Should Know
Pfizer (PFE) closed at $36.82 in the latest trading session, marking a -0.24% move from the prior day.
- American City Business Journals
Ex-FDA commissioner Gottlieb wants to keep his Boston speech 'off-the-record'
Members of the media planning to attend the conference were told Friday that Gottlieb’s comments was “candid and off-the-record, not to be recorded,” according to an email sent to the Business Journal.
- Zacks
Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert
The FDA approves new warnings about inflammation risk to be added to labels of Pfizer's (PFE) Ibrance, Eli Lilly's (LLY) Verzenio and Novartis' (NVS) Kisqali.
- Zacks
Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others
Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
- Zacks
Renal Cell Carcinoma Space in Focus: Some Key Developments
The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.
- GuruFocus.com
Gilead Tops List of Most Innovative Drug Companies
Index ranks ability of pharma companies to bring drugs from early testing to market and make them successful Continue reading...
- InvestorPlace
Dow Jones Today: Plenty of Good News
With the help of broad-based leadership, the major U.S. equity benchmarks rallied Wednesday amid a flurry of decent headlines. Today's leadership came by way of the technology and healthcare sectors, the two largest sector weights in the S&P 500, with some contributions from the defensive, high-yielding utilities group.Source: Shutterstock President Donald Trump took to Twitter (NYSE:TWTR), something that doesn't always end well for investors, to encourage the Federal Reserve to take interest rates to zero or even negative. It's unlikely the Fed follows the advice of going to negative rates, at least not anytime soon, but another rate cut does appear imminent if Fed funds futures are to be believed. * 10 Stocks to Sell in Market-Cursed September Adding to today's ebullience was news out of China that the country will exempt certain U.S. goods from 25% tariffs that were deployed last year. This is the latest sign that the trade talks the two countries are expected to hold next month could actually happen and that the results could be positive.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThose catalysts were enough to send the Nasdaq Composite higher by 1.06% while the S&P 500 gained 0.72%. The Dow Jones Industrial Average jumped 0.85%. Much of the strength in the blue chip index was attributable to its larger components as, in late trading, just 16 of the Dow's 30 residents were trading to the upside. Boeing Triumphs AgainTry as I might to mention different Dow names from day-to-day, Boeing (NYSE:BA) is the index's largest component and when it's the best-performing Dow stock on a given day, as it was Wednesday, it bears mentioning.The aerospace and defense giant rallied 3.50% today after CEO Dennis Muilenberg made some positive though not earth-shattering comments about Boeing's efforts to get the 737 MAX jet back in the skies."We're continuing to make solid progress on return to service," said the CEO at an investor conference in California. "We're actively engaged with regulators around the world and day-to-day working with the FAA on return-to-service timing." AAPL Stock Hits $1 Trillion AgainA day after its new product launch event, Apple (NASDAQ:AAPL) performed better than it did yesterday, gaining 3.18% to rank as the second-best Dow performer behind Boeing, pushing the stock back into the exclusive $1 trillion market value club for the first time this year. Predictably, analysts were chatty about Apple stock today following news of iPhone enhancements and that the Apple + streaming service will be less expensive, at least for now, than competing options.Needham analyst Laura Martin reiterated her "strong buy" rating on Apple stock while boosting her price target to $250 from $225, implying upside of more than 10% from Wednesday's close. Encouraging SignAs noted earlier, the healthcare sector was a big contributor the broader market's Wednesday upside and three of the Dow's four healthcare names traded higher today with Pfizer (NYSE:PFE) being the only offender of the quartet.Granted, it's just one day, but it's nice to see some strength in the pharmaceuticals stocks because this group could face more headwinds as the 2020 presidential campaign unfolds. With that in mind, House Democrats are looking for ways cobble together a plan that would alter how Medicare pays for drugs while President Trump has and will continue to tout falling drug prices.While brand name prices are still increasing, the president can lean on declining generic prices in what is sure to be a hot-button campaign issue. This is a bipartisan issue, rare as those are, and that presents some risks going forward. Bottom Line in Dow Jones TodayI recently mentioned signs that value stocks are making a comeback against their growth rivals. Some market observers may overstate the consequences in that scenario. It's not all bad when considering decent percentages of the Dow Jones Industrial Average and S&P 500 are classified as value stocks.What would be positive for the sustainability of this mini-rally is strength in maligned small caps and that scenario is emerging. The Russell 2000 Index jumped more than 2% and that could be a sign stocks are poised to defy usually gloomy September expectations. Importantly, that index came into Wednesday with a gain of almost 5% over the past week.Todd Shriber does not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Sell in Market-Cursed September * 7 of the Worst IPO Stocks in 2019 * 7 Best Stocks That Crushed It This Earnings Season The post Dow Jones Today: Plenty of Good News appeared first on InvestorPlace.
- GuruFocus.com
Leaner Pfizer Positioned to Boost R&D Output
Company’s recent decisions will enable it to concentrate on building core business Continue reading...
- Zacks
4 Big Drugmakers Boasting Impressive Oncology Pipelines
We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
- Reuters
Merck KGaA lung cancer drug is 3rd on U.S. watchdog's priority lane
Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation. Novartis last week won the breakthrough therapy tag, which puts it on a fast track for regulatory review, for its capmatinib drug. Pfizer's Xalkori drug was given the designation https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_xalkori_crizotinib_receives_fda_breakthrough_therapy_designation_in_two_new_indications-0 last year.
- Zacks
Pfizer's Pneumococcal Vaccine Shows Potential in Infants
Pfizer (PFE) announces positive preliminary data from mid-stage study evaluating its 20-valent pneumococcal conjugate vaccine in infants. Completes enrollment in late-stage studies on the vaccine in adults.
- Zacks
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Pfizer (PFE) closed at $37.37, marking a +1.47% move from the previous day.
- Investor's Business Daily
Pelosi Drug Pricing Plan Puts Big Pharma In 2020 Election Hot Seat
The House Speaker Nancy Pelosi drug pricing plan aims to turn the 2020 election into a referendum on Big Pharma and Medicare drug prices.
- Zacks
ACADIA Surges on Early Success of Nuplazid Dementia Study
ACADIA Pharmaceuticals' (ACAD) Parkinson's psychosis drug, Nuplazid, meets primary endpoint earlier than expected in late-stage label expansion study evaluating it in patients with dementia-related psychosis.
- American City Business Journals
Aveo CEO says new data eases concerns about troubled kidney cancer drug
In the two-year study of 350 subjects who had taken two previous cancer treatments, Aveo Oncology's renal cell carcinoma treatment tivozanib was linked to a lower risk of death than the current standard of care.
